Sana Biotechnology SANA Success Payment Liabilities Noncurrent
Success Payment Liabilities Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept sana:SuccessPaymentLiabilitiesNoncurrent.
The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sana Biotechnology's success payment liabilities noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sana Biotechnology's success payment liabilities noncurrent?
- Sana Biotechnology (SANA) reported success payment liabilities noncurrent of $16.93M in Q1 2026.
- How has Sana Biotechnology's success payment liabilities noncurrent changed year-over-year?
- Sana Biotechnology's success payment liabilities noncurrent increased by 264.1% year-over-year, from $4.65M to $16.93M.
- What is the long-term trend for Sana Biotechnology's success payment liabilities noncurrent?
- Over 5 years (2020 to 2025), Sana Biotechnology's success payment liabilities noncurrent has grown at a -24.1% compound annual growth rate (CAGR), from $76.49M to $19.24M.
- What does success payment liabilities noncurrent mean?
- This represents long-term contractual obligations to make payments to third parties or partners upon the successful attainment of specific clinical, regulatory, or commercial milestones. These liabilities are distinct from standard debt and are tied directly to the progress of the company's research and development pipeline. Tracking this metric helps investors evaluate the company's future capital commitments associated with the advancement of its therapeutic programs.